Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin

S. Li, E. Kimura, B. M. Fall, Morayma Reyes Gil, J. C. Angello, R. Welikson, S. D. Hauschka, J. S. Chamberlain

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Gene therapy for Duchenne muscular dystrophy (DMD) will require sustained expression of therapeutic dystrophins in striated muscles. Lentiviral vectors have a relatively large transgene carrying capacity and can integrate into nondividing cells. We therefore explored the use of lentiviral vectors for transferring genes into mouse skeletal muscle cells. These vectors successfully transferred a minidystrophin expression cassette into mdx muscles, and minidystrophin expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months. However, only low to moderate levels of skeletal muscle transduction could be obtained by intramuscular injection of the highest currently available lentiviral doses. Using cultured cells, the lentiviral vectors effectively transduced proliferating and terminally differentiated muscle cells, indicating that cell cycling is not essential for transduction of myogenic cells. We further showed that lentiviral vectors efficiently transduced both primary myoblasts and multipotent adult progenitor cells (MAPCs) in vitro, and the cells persistently expressed transgenes without any obvious toxicity. When mdx primary myoblasts were genetically modified with minidystrophin vectors and transplanted into mdx skeletal muscles, significant numbers of dystrophin-expressing myofibers formed. Finally, we showed that a short, highly active CK6 regulatory cassette directed muscle-specific activity in the context of the lentiviral vectors. The ability of lentiviral vectors to transduce myogenic progenitors using a minidystrophin cassette regulated by a muscle-specific promoter suggests that this system could be useful for ex vivo gene therapy of muscular dystrophy.

Original languageEnglish (US)
Pages (from-to)1099-1108
Number of pages10
JournalGene Therapy
Volume12
Issue number14
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Muscles
Dystrophin
Skeletal Muscle
Myoblasts
Transgenes
Genetic Therapy
Muscle Cells
Striated Muscle
Duchenne Muscular Dystrophy
Muscular Dystrophies
Intramuscular Injections
Conservation of Natural Resources
Cultured Cells
Stem Cells
Genes
Therapeutics
In Vitro Techniques

Keywords

  • CK6
  • DMD
  • Gene transfer
  • mdx-lentiviral vector
  • Mini-dystrophin
  • Myogenic progenitors

ASJC Scopus subject areas

  • Genetics

Cite this

Li, S., Kimura, E., Fall, B. M., Reyes Gil, M., Angello, J. C., Welikson, R., ... Chamberlain, J. S. (2005). Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Therapy, 12(14), 1099-1108. https://doi.org/10.1038/sj.gt.3302505

Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. / Li, S.; Kimura, E.; Fall, B. M.; Reyes Gil, Morayma; Angello, J. C.; Welikson, R.; Hauschka, S. D.; Chamberlain, J. S.

In: Gene Therapy, Vol. 12, No. 14, 07.2005, p. 1099-1108.

Research output: Contribution to journalArticle

Li, S, Kimura, E, Fall, BM, Reyes Gil, M, Angello, JC, Welikson, R, Hauschka, SD & Chamberlain, JS 2005, 'Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin', Gene Therapy, vol. 12, no. 14, pp. 1099-1108. https://doi.org/10.1038/sj.gt.3302505
Li, S. ; Kimura, E. ; Fall, B. M. ; Reyes Gil, Morayma ; Angello, J. C. ; Welikson, R. ; Hauschka, S. D. ; Chamberlain, J. S. / Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. In: Gene Therapy. 2005 ; Vol. 12, No. 14. pp. 1099-1108.
@article{172f566bfb994698baf3859aa4c56f33,
title = "Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin",
abstract = "Gene therapy for Duchenne muscular dystrophy (DMD) will require sustained expression of therapeutic dystrophins in striated muscles. Lentiviral vectors have a relatively large transgene carrying capacity and can integrate into nondividing cells. We therefore explored the use of lentiviral vectors for transferring genes into mouse skeletal muscle cells. These vectors successfully transferred a minidystrophin expression cassette into mdx muscles, and minidystrophin expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months. However, only low to moderate levels of skeletal muscle transduction could be obtained by intramuscular injection of the highest currently available lentiviral doses. Using cultured cells, the lentiviral vectors effectively transduced proliferating and terminally differentiated muscle cells, indicating that cell cycling is not essential for transduction of myogenic cells. We further showed that lentiviral vectors efficiently transduced both primary myoblasts and multipotent adult progenitor cells (MAPCs) in vitro, and the cells persistently expressed transgenes without any obvious toxicity. When mdx primary myoblasts were genetically modified with minidystrophin vectors and transplanted into mdx skeletal muscles, significant numbers of dystrophin-expressing myofibers formed. Finally, we showed that a short, highly active CK6 regulatory cassette directed muscle-specific activity in the context of the lentiviral vectors. The ability of lentiviral vectors to transduce myogenic progenitors using a minidystrophin cassette regulated by a muscle-specific promoter suggests that this system could be useful for ex vivo gene therapy of muscular dystrophy.",
keywords = "CK6, DMD, Gene transfer, mdx-lentiviral vector, Mini-dystrophin, Myogenic progenitors",
author = "S. Li and E. Kimura and Fall, {B. M.} and {Reyes Gil}, Morayma and Angello, {J. C.} and R. Welikson and Hauschka, {S. D.} and Chamberlain, {J. S.}",
year = "2005",
month = "7",
doi = "10.1038/sj.gt.3302505",
language = "English (US)",
volume = "12",
pages = "1099--1108",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "14",

}

TY - JOUR

T1 - Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin

AU - Li, S.

AU - Kimura, E.

AU - Fall, B. M.

AU - Reyes Gil, Morayma

AU - Angello, J. C.

AU - Welikson, R.

AU - Hauschka, S. D.

AU - Chamberlain, J. S.

PY - 2005/7

Y1 - 2005/7

N2 - Gene therapy for Duchenne muscular dystrophy (DMD) will require sustained expression of therapeutic dystrophins in striated muscles. Lentiviral vectors have a relatively large transgene carrying capacity and can integrate into nondividing cells. We therefore explored the use of lentiviral vectors for transferring genes into mouse skeletal muscle cells. These vectors successfully transferred a minidystrophin expression cassette into mdx muscles, and minidystrophin expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months. However, only low to moderate levels of skeletal muscle transduction could be obtained by intramuscular injection of the highest currently available lentiviral doses. Using cultured cells, the lentiviral vectors effectively transduced proliferating and terminally differentiated muscle cells, indicating that cell cycling is not essential for transduction of myogenic cells. We further showed that lentiviral vectors efficiently transduced both primary myoblasts and multipotent adult progenitor cells (MAPCs) in vitro, and the cells persistently expressed transgenes without any obvious toxicity. When mdx primary myoblasts were genetically modified with minidystrophin vectors and transplanted into mdx skeletal muscles, significant numbers of dystrophin-expressing myofibers formed. Finally, we showed that a short, highly active CK6 regulatory cassette directed muscle-specific activity in the context of the lentiviral vectors. The ability of lentiviral vectors to transduce myogenic progenitors using a minidystrophin cassette regulated by a muscle-specific promoter suggests that this system could be useful for ex vivo gene therapy of muscular dystrophy.

AB - Gene therapy for Duchenne muscular dystrophy (DMD) will require sustained expression of therapeutic dystrophins in striated muscles. Lentiviral vectors have a relatively large transgene carrying capacity and can integrate into nondividing cells. We therefore explored the use of lentiviral vectors for transferring genes into mouse skeletal muscle cells. These vectors successfully transferred a minidystrophin expression cassette into mdx muscles, and minidystrophin expression persisted and prevented subsequent muscle fiber degeneration for at least 6 months. However, only low to moderate levels of skeletal muscle transduction could be obtained by intramuscular injection of the highest currently available lentiviral doses. Using cultured cells, the lentiviral vectors effectively transduced proliferating and terminally differentiated muscle cells, indicating that cell cycling is not essential for transduction of myogenic cells. We further showed that lentiviral vectors efficiently transduced both primary myoblasts and multipotent adult progenitor cells (MAPCs) in vitro, and the cells persistently expressed transgenes without any obvious toxicity. When mdx primary myoblasts were genetically modified with minidystrophin vectors and transplanted into mdx skeletal muscles, significant numbers of dystrophin-expressing myofibers formed. Finally, we showed that a short, highly active CK6 regulatory cassette directed muscle-specific activity in the context of the lentiviral vectors. The ability of lentiviral vectors to transduce myogenic progenitors using a minidystrophin cassette regulated by a muscle-specific promoter suggests that this system could be useful for ex vivo gene therapy of muscular dystrophy.

KW - CK6

KW - DMD

KW - Gene transfer

KW - mdx-lentiviral vector

KW - Mini-dystrophin

KW - Myogenic progenitors

UR - http://www.scopus.com/inward/record.url?scp=22744459591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22744459591&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3302505

DO - 10.1038/sj.gt.3302505

M3 - Article

C2 - 15759015

AN - SCOPUS:22744459591

VL - 12

SP - 1099

EP - 1108

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 14

ER -